VIGIL NEUROSCIENCE INC (VIGL)
US92673K1088 - Common Stock
We assign a fundamental rating of 2 out of 10 to VIGL. VIGL was compared to 565 industry peers in the Biotechnology industry. The financial health of VIGL is average, but there are quite some concerns on its profitability. VIGL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year VIGL has reported negative net income.
In the past year VIGL has reported a negative cash flow from operations.
1.2 Ratios
With a Return On Assets value of -62.92%, VIGL is not doing good in the industry: 61.21% of the companies in the same industry are doing better.
With a Return On Equity value of -93.28%, VIGL perfoms like the industry average, outperforming 47.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.92% | ||
| ROE | -93.28% | ||
| ROIC | N/A |
ROA(3y)-45.01%
ROA(5y)N/A
ROE(3y)-51.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VIGL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VIGL has more shares outstanding than it did 1 year ago.
VIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -3.55, we must say that VIGL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.55, VIGL perfoms like the industry average, outperforming 45.02% of the companies in the same industry.
VIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.55 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 3.72 indicates that VIGL has no problem at all paying its short term obligations.
VIGL's Current ratio of 3.72 is in line compared to the rest of the industry. VIGL outperforms 43.77% of its industry peers.
A Quick Ratio of 3.72 indicates that VIGL has no problem at all paying its short term obligations.
With a Quick ratio value of 3.72, VIGL perfoms like the industry average, outperforming 45.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
The earnings per share for VIGL have decreased by -0.98% in the last year.
EPS 1Y (TTM)-0.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
VIGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.02% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.6%
EPS Next 2Y2.56%
EPS Next 3Y4.18%
EPS Next 5Y19.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VIGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIGL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.56%
EPS Next 3Y4.18%
5. Dividend
5.1 Amount
No dividends for VIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIGIL NEUROSCIENCE INC
NASDAQ:VIGL (12/24/2024, 7:44:12 PM)
After market: 1.62 -0.01 (-0.61%)1.63
+0.05 (+3.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.38%
Inst Owner Change2.56%
Ins Owners13.19%
Ins Owner Change0.74%
Market Cap66.63M
Analysts84.29
Price Target16.19 (893.25%)
Short Float %2.61%
Short Ratio4.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.36%
Min EPS beat(2)7.31%
Max EPS beat(2)15.41%
EPS beat(4)3
Avg EPS beat(4)9.3%
Min EPS beat(4)-4.62%
Max EPS beat(4)19.09%
EPS beat(8)7
Avg EPS beat(8)9.77%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.59%
EPS NY rev (1m)2.76%
EPS NY rev (3m)4.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.75 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.06
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS2.17
TBVpS2.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.92% | ||
| ROE | -93.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-45.01%
ROA(5y)N/A
ROE(3y)-51.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.23% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | -3.55 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)661.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.32%
EPS Next Y2.6%
EPS Next 2Y2.56%
EPS Next 3Y4.18%
EPS Next 5Y19.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.11%
EBIT Next 3Y-19.65%
EBIT Next 5YN/A
FCF growth 1Y26.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.71%
OCF growth 3YN/A
OCF growth 5YN/A